Akthelia Pharmaceuticals will present exciting new translational efficacy data on mucosal barrier injury, and its partnering and capital raising objectives at the Nordic Life Science Days, 18-19 September 2024 in Malmö, Sweden
REYKJAVIK, Iceland -- 9 Sept, 2024 -- Akthelia Pharmaceuticals, a pioneering company focused on gastrointestinal health and mucosal barrier integrity (MBI), is excited to announce its participation in the Nordic Life Science Days 2024 (NLSD) in Malmö, Sweden. The annual event is one of the largest life science conferences in the Nordic region, bringing together industry leaders, innovators, and investors from across the globe.
Akthelia’s CEO, Egill Masson, will present the company’s leading development program for AKT-011, an innovative therapeutic candidate aimed at addressing mucosal barrier injury, fundamental to the pathogenesis of many large indications in oncology, gastroenterology and other areas of medicine. Currently in preclinical development, AKT-011—under the working name Gastrimod® —holds potential for treating a variety of conditions, including gastrointestinal disorders and inflammation caused by cancer treatments, which are areas of significant unmet medical need.
"Our data demonstrates promising translational efficacy and we are keen to share our progress on Gastrimod / AKT-011," said Egill Masson, "Akthelia’s focus on preserving and restoring the integrity of the gastrointestinal mucosal barrier has led to promising early data, and we are eager to engage with partners and investors who share our vision for transforming patient care and are interested to work with us to move this asset into the clinic."
During the presentation, Akthelia will also discuss its strategic roadmap, highlighting the steps towards clinical development. The company’s management team has been in discussions with multiple partners to advance AKT-011, including recent meetings with Industrifonden, which has shown interest in co-investing pending lead investor commitment.
Akthelia Pharmaceuticals is confident that its participation at the NLSD will further its efforts to build alliances within the life sciences community and support the development of life-changing therapies.
"Our data demonstrates promising translational efficacy and we are keen to share our progress on Gastrimod / AKT-011. Akthelia’s focus on preserving and restoring the integrity of the gastrointestinal mucosal barrier has led to promising early data, and we are eager to engage with partners and investors who share our vision for transforming patient care and are interested to work with us to move this asset into the clinic."
With the European Commission's Seal of Excellence as a testament to its innovative approach, Akthelia is now actively seeking strategic partnerships and funding opportunities to propel its lead programs, including AKT-011 for mucosal barrier injury and AKT-021 for wound healing, towards clinical success.
To arrange a meeting, please contact CEO Egill Masson, egill.masson@aktheliapharma.com.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals is a pioneering biopharmaceutical company, focusing on therapeutics that target mucosal barrier injury and epithelial integrity, via a novel biology-driven immunotherapeutic strategy that upregulates epithelial surfaces.
Akthelia lead program is a late preclinical stage asset with potential to be a first-in-class oral therapeutic addressing the large unmet need to improve cancer care outcomes by reducing the risk of chemotherapy-induced bloodstream infections. Akthelia's platform also addresses the urgent global threat of antibiotic bacterial resistance (AMR).
CONTACTS
Egill Masson CEO egill.masson@aktheliapharma.com
Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland